Bod Science Limited Quarterly Activities Report

Bod Science Limited (ASX: BOD), a cannabis-focused drug development and product innovation company, reported a net cash outflow of AU$4k in Q1 FY2025, reflecting reduced costs since entering voluntary administration in November 2023. Quarterly receipts rose by 176% to AU$149k, driven by higher sales volumes and resumed payments from a major distributor. Additionally, Biortica Agrimed Limited provided AU$356k to cover operating expenses.

 Bod is operating under a Deed of Company Arrangement (DOCA) with Biortica, with efforts ongoing to finalize a Share Purchase Agreement and meet ASX re-compliance requirements. The extraordinary general meeting of shareholders, initially planned for September 2024, has been postponed to November 2024. Bod continues to pursue clinical trial pathways and develop cannabis-based medicines, leveraging partnerships with corporate collaborators and research organizations.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com